Resihance Tablet (Regorafenib)

Introduction of Resihance Tablet (Regorafenib)

Regorafenib Tablet, sold under the brand name Resihance, is a medication used in the treatment of certain types of cancer. It belongs to the class of drugs known as kinase inhibitors and specifically targets multiple enzymes involved in tumor growth and angiogenesis (the formation of new blood vessels). The primary ingredient in Regorafenib is regorafenib itself, which inhibits several proteins that play a crucial role in tumor cell proliferation, survival, and angiogenesis.  Stivarga is another name commonly associated with Regorafenib Tablet. It is the brand name under which Regorafenib is marketed in certain countries. Stivarga and Resihance contain the same active ingredient, regorafenib, and have similar indications and dosing guidelines. The choice of brand name may vary depending on the region and pharmaceutical manufacturer.

Dosage Information and Uses of Regorafenib Tablet (Resihance)

The dosage of Regorafenib Tablet should be determined by a qualified healthcare professional based on the individual patient's condition and response to treatment. The tablets are taken orally, with or without food, once a day for 21 days, followed by a 7-day break, constituting a 28-day treatment cycle. The recommended dose is usually 160 mg (four tablets of 40 mg) taken once daily.

Regorafenib Tablet is primarily used in the treatment of metastatic colorectal cancer (CRC) that has progressed after prior treatment. It is also indicated for the treatment of advanced gastrointestinal stromal tumors (GIST) that cannot be surgically removed or have progressed after prior treatment with other medications. Additionally, it is approved for the treatment of hepatocellular carcinoma (HCC) in patients who have previously received sorafenib.

Regorafenib Tablet Manufacturer:

Regorafenib Tablet (Resihance) is manufactured by various pharmaceutical companies. The specific manufacturer may vary depending on the country and region. It is important to ensure that the medication is obtained from a reputable manufacturer to guarantee its quality, safety, and effectiveness. Consulting with a healthcare professional or pharmacist can help provide information on authorized manufacturers in a particular region.

Regorafenib Tablet Availability at onlinegenericmedicine.com:

The availability of Regorafenib Tablet (Resihance) at onlinegenericmedicine.com may vary depending on the website's stock and regulations governing the sale of prescription medications. Onlinegenericmedicine.com is an online platform that provides access to a wide range of generic medicines, including Regorafenib Tablet. 

Regorafenib Tablet Brand Name:

The brand name of Regorafenib Tablet may vary depending on the manufacturer and the country where it is marketed. In some regions, it is known as Resihance, while in others, it may be marketed under the brand name Stivarga. The choice of brand name is determined by the pharmaceutical company marketing the medication and the regulatory authorities in each country. Regardless of the brand name, the active ingredient remains regorafenib, providing the same therapeutic effects.

In summary, Regorafenib Tablet (Resihance) is a kinase inhibitor used for the treatment of metastatic colorectal cancer, advanced gastrointestinal stromal tumors, and hepatocellular carcinoma. It is available under different brand names such as Resihance and Stivarga, depending on the manufacturer and region. The dosage should be determined by a healthcare professional, and caution should be exercised when purchasing medication online, to ensure the authenticity and reliability of the source.

Side Effect of Resihance Tablet (Regorafenib)

• Common side effects of Regorafenib may include fatigue, weakness, decreased appetite, weight loss, hypertension (high blood pressure), diarrhea, nausea, vomiting, abdominal pain, and constipation. These side effects are generally manageable and should be reported to the healthcare provider if severe or persistent.
• Hand-foot skin reaction (HFSR) is a common side effect of Regorafenib. It may cause redness, swelling, pain, blisters, or calluses on the palms of the hands or soles of the feet. Good skin care practices and avoiding excessive pressure on the affected areas can help alleviate symptoms.
• Liver toxicity, indicated by increased liver enzyme levels, can occur with Regorafenib use. Regular liver function tests should be performed during treatment to monitor for any abnormalities.
• Hemorrhage (bleeding) is a potential side effect of Regorafenib. Symptoms such as unusual bleeding, easy bruising, or blood in stools should be promptly reported to the healthcare provider.
• Gastrointestinal perforation, a rare but serious side effect, may occur with Regorafenib/Stivarga use. Signs of perforation, such as severe abdominal pain, fever, and chills, should be immediately reported to a healthcare professional.
• Cardiac events, including heart attack or heart failure, have been reported in some patients taking Regorafenib. Any symptoms of chest pain, shortness of breath, or rapid weight gain should be reported immediately.
• Wound healing complications, such as delayed wound healing or wound dehiscence, have been observed with Regorafenib. It is important to inform healthcare providers about the use of Regorafenib before undergoing any surgical procedures.
• Other less common side effects may include hypothyroidism, voice changes, hoarseness, muscle pain, joint pain, headache, dizziness, or changes in taste.
  
  

Precautions of Resihance Tablet (Regorafenib)

• Before initiating treatment with Regorafenib Tablet, it is crucial to inform your healthcare provider about any pre-existing medical conditions, including liver problems, bleeding disorders, heart diseases, hypertension, and gastrointestinal perforation.
• Women who are pregnant or planning to become pregnant should avoid using Regorafenib, as it can cause harm to the unborn baby. Adequate contraception should be used during treatment and for at least two months after the last dose.
• Breastfeeding should be avoided while taking Regorafenib, as it is unknown whether the medication passes into breast milk and could harm the nursing infant.
• Regorafenib may cause hypertension (high blood pressure), so regular monitoring of blood pressure is essential during treatment. Medications may be prescribed to manage hypertension if necessary.
• Patients may experience hand-foot skin reaction (HFSR) characterized by redness, swelling, pain, and/or blisters on the palms of the hands or soles of the feet. Proper foot care, including moisturizing and avoiding excessive pressure on the affected areas, is recommended.
• Regorafenib may affect wound healing, so it is advisable to avoid invasive dental procedures and major surgeries during treatment. It is important to inform your dentist or surgeon about the use of Regorafenib beforehand.

Regorafenib Tablet Online Purchase at onlinegenericmedicine.com:

Onlinegenericmedicine.com offers the option to purchase Regorafenib Tablet (Resihance) online, subject to applicable regulations and restrictions. The online purchase of prescription medications should be done with caution. It is advisable to consult a healthcare professional before purchasing medications online to ensure appropriate dosage, safety, and suitability for the individual's condition.

Drug Interactions with Resihance Tablet (Regorafenib)

• Inform your healthcare provider about all medications, including prescription, over-the-counter drugs, vitamins, and herbal supplements you are taking, as they may interact with Regorafenib/Stivarga.
• Regorafenib can interact with medications that affect liver enzymes, such as CYP3A4 inducers (e.g., rifampin, carbamazepine) or inhibitors (e.g., ketoconazole, clarithromycin). These interactions may alter the concentration of Regorafenib in the body, affecting its efficacy or increasing the risk of side effects.
• The concomitant use of Regorafenib with anticoagulants (blood thinners) or antiplatelet drugs may increase the risk of bleeding. Close monitoring of bleeding parameters and adjustments in the dosage of these medications may be necessary.
• Regorafenib may increase the concentration of certain drugs that are substrates of CYP2C9, CYP2C19, or CYP3A4 enzymes, potentially leading to increased side effects. Dose adjustments or alternatives should be considered in such cases.
• Avoid the use of strong CYP3A4 inducers or inhibitors while taking Regorafenib, as they can significantly affect the concentration of Regorafenib in the body.
  
  

FAQs

Resihance Tablet (Regorafenib)

Can Regorafenib Tablet be taken on an empty stomach?

Regorafenib Tablet can be taken with or without food. However, taking it with food may help reduce gastrointestinal side effects such as nausea and vomiting. Follow the instructions provided by your healthcare provider regarding the administration of Regorafenib with or without food.

Can Regorafenib Tablet be used in elderly patients?

Regorafenib can be used in elderly patients; however, caution should be exercised due to the potential for age-related comorbidities and decreased organ function. Close monitoring of side effects and adjustment of dosage may be necessary based on the individual patient's health status.

How long does it take for Regorafenib Tablet/Stivarga to show its effectiveness?

The effectiveness of Regorafenib Tablet can vary among individuals and depends on the specific cancer being treated. It may take several weeks or months to see the full benefits of the medication. Your healthcare provider will monitor your response to treatment through regular check-ups, imaging scans, and laboratory tests.

Can Regorafenib Tablet be used in patients with liver problems?

Regorafenib should be used with caution in patients with liver problems. It is essential to inform your healthcare provider about any pre-existing liver conditions before starting treatment. Liver function tests will be performed regularly to monitor the effects of Regorafenib on liver enzymes. The dosage may need to be adjusted based on the individual's liver function and the severity of the liver condition.